JTI Plans to Enter Korean HNB Market in H1 2024

JTI by 2FIRSTS.ai
Jan.10.2024
JTI Plans to Enter Korean HNB Market in H1 2024
Japan Tobacco International (JTI) is preparing to enter the South Korean market, adding heated tobacco sticks to convenience store shelves.

According to a report by South Korean media outlet, etoday, on January 9th, Japan Tobacco International (JTI) is ready to enter the South Korean market, driven by the success of KT&G and Philip Morris International (PMI) in the heated tobacco market (HNB).

 

According to industry sources, Japan Tobacco International (JTI) Korea is expected to introduce heated tobacco sticks to convenience store cigarette shelves in Korea in the first half of this year. This move is seen by the tobacco industry as part of JTI Korea's efforts to launch a new type of e-cigarette. Currently, JTI Korea does not sell HNB (heat-not-burn) tobacco and tobacco stick products in the area.

 

Since 2022, JTI has registered over 100 design patents related to e-cigarettes with the Korean Intellectual Property Office. These patents encompass all aspects of e-cigarette devices and associated components, including the trademark for their newly launched HNB product, "Ploom X," which is currently being sold in Japan.

 

Japan Tobacco International (JTI) is a Japanese tobacco company headquartered in Geneva, Switzerland, and operates a subsidiary called JTI Korea in South Korea. Although JTI introduced its liquid pod-based e-cigarette product, Ploom Tech, in South Korea in 2019, the company discontinued its sales in 2021. However, due to JTI's global expansion of its e-cigarette business, the industry is optimistic about JTI Korea's prospects in the South Korean e-cigarette market.

 

A representative from JTI Korea stated that the plans to release e-cigarettes have not been finalized yet, but they are continuously considering various possibilities to enter the e-cigarette market in Korea based on consumer demand and industry trends.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Fiscal benefit, not health, strongest indicator for vape bans – Contributed by Samrat Chowdhery
Fiscal benefit, not health, strongest indicator for vape bans – Contributed by Samrat Chowdhery
Data shows 75% of nations with state stakes in tobacco trade ban modern substitutes compared to 10% in the free-market group. What is driving these divergent regulations?
Feb.04
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
A Fifth Circuit panel upheld the U.S. Food and Drug Administration’s 2021 final rule requiring companies seeking premarket authorization for new tobacco products to include information on health-risk investigations. In a published opinion, the court found FDA satisfied the Regulatory Flexibility Act’s procedural requirements and reasonably relied on the economic analysis from the 2016 “deeming rule” as a factual basis to certify limited impact on small businesses.
Feb.27 by 2FIRSTS.ai
Philippines DTI Floats Blanket Ban on Open-Pod Vapes and E-Liquids, Seeks Public Input
Philippines DTI Floats Blanket Ban on Open-Pod Vapes and E-Liquids, Seeks Public Input
Philippines’ Department of Trade and Industry (DTI) is inviting stakeholder feedback on a draft Department Administrative Order (DAO) that would impose a blanket ban on open vape pods and e-liquids—covering use, manufacturing, importation, and distribution.
Jan.29 by 2FIRSTS.ai
Kumulus Vape launches Labster production unit for e-liquids and DIY concentrates
Kumulus Vape launches Labster production unit for e-liquids and DIY concentrates
Kumulus Vape has launched Labster, a 700 sq m production unit in the Lyon Metropolis near the group’s headquarters, for e-liquids and DIY concentrates. The site is equipped with automated lines supplied by CDA (Constructions d’Automatismes) to carry out bottling and labeling. Its theoretical capacity is described as several million bottles per year in 10–100 ml formats, and it is already operational.
Feb.06 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
European survey: current e-cigarette use among 15–19-year-olds rises from 14% (2019) to 22% (2024)
European survey: current e-cigarette use among 15–19-year-olds rises from 14% (2019) to 22% (2024)
A European study cited in the report says the share of young people aged 15 to 19 who are current e-cigarette users increased from 14% in 2019 to 22% in 2024, with Italy reflecting the broader European pattern. Over the same period, conventional cigarette smoking among young people is described as declining, with the proportion of students who have smoked at least once in their lifetime falling sharply from 1995 to 2024, and the largest drop occurring between 2019 and 2024.
Feb.12 by 2FIRSTS.ai